Hu Shanlian served as editor-in-chief of the 16th Edition of the World Clinical Drugs, which was held in Shanghai.

On July 26, 2020, on the occasion of the 40th anniversary of the publication of The World Clinical Drugs, the 16th Editorial Committee of The World Clinical Drugs was successfully convened in Shanghai.hundreds of editorial boards, academic experts and business representatives from Shanghai, Beijing, Guangzhou, Tianjin, Wuhan, Nanjing and other parts of the country gathered to witness the establishment of the new editorial board.an excellent scientific and technological journal is closely related to the academic strength of the editor-in-chief and the editorial board.well known, Hu Shanlian, a professor at Fudan University's School of Public Health, is the founder and leader of the development of health economics in China.this time, Professor Hu accepted the invitation to become the new editor-in-chief of the World Clinical Drugs, but also make the editorial board of the journal in the previous to clinicians and pharmacists mainly based on the comprehensive increase of the national drug economics and drug management research research leaders, really let the journal "focus on comprehensive drug evaluation, promote clinical rational drug use" to the real place, but also let the industry on the "world clinical drugs" the future development of the future development, have greater expectations and imagination.the editorial board, the organizers led Wei Shuyuan, president of the General Institute of Pharmaceutical Industry Research in China, to issue a letter of appointment to Professor Hu Shanlian.the appointment ceremony of the editor-in-chief, Hu Shanlian in the editor-in-chief's message, said that this Fudan University School of Public Health and information center cooperation, is based on the original content of the "addition." After, we will explore in depth the safety, effectiveness, economy, innovation, adaptability and accessibility of clinical applications of drugs to meet the needs of medical and health care reform and health care reform. "The World Clinical Medicine is a high-quality academic journal," said Wei Shuyuan, president of the China Pharmaceutical Industry Research Institute in. as the organizer of the, the China Pharmaceutical Industry Research Institute will fully support and, as always, contribute to the innovation of China's pharmaceutical industry and the reform and innovation of scientific and technological journals." as a contractor, China Pharmaceutical Industry Information Center Director Guo Wen said in a statement, "World Clinical Medicine" is our industry-based high-service clinical, service enterprises link., we attach great importance to the growth and development of periodicals, and hope that through unremitting efforts to make it a first-class journal brand in the field of medicine, in the process, the information center will also provide the growth and development of journals with the necessary information data and platform resources support. The appointment ceremony of the deputy editor-in-chief was also held at themeeting, the new vice-editor (sorted by last name), Professor Chen Wen of Fudan University School of Public Health, Professor Chen Wei, Director of the Ruijin North Hospital affiliated with Shanghai Jiaotong University School of Medicine, Professor Fan Guorong, Director of Clinical Medicine Department of the First People's Hospital affiliated with Shanghai Jiaotong University, Professor He Xijing, Dean of Xi'an International Rehabilitation Medical Center, and Professor Li Bin, Vice President of The Chinese Medicine University Yueyang Chinese And Western Medicine Hospital Professor Lu Hongzhou, Party Secretary and Chief Physician of Shanghai Public Health Clinical Center (affiliated with Fudan University), Professor Wang Jiguang, Director of Shanghai Hypertension Research Institute, Dr. Xie Xiaoxuan, Director of Tongji Hospital affiliated with Tongji University, Fudan University School of Public Health, Professor Yinghua, Director of the National Health And Health Commission Health Development Research Center, Deputy Director of the National Health and Health Commission's Comprehensive Drug and Technology Assessment Center, And iA, Dr. Zhou Xin, Director of Respiratory and Critical Care Medicine at Shanghai First People's Hospital.Deputy Editor-in-Chief Zhou Xin, Lu Hongzhou Deputy Editor-in-Chief and Chen Wen Deputy Editor-in-Chief, respectively, spoke.Zhou Xin Deputy Editor said that in the future, under the leadership of Hu, the organic combination of clinical application of drugs and drug economics will be discussed in depth to further strengthen the publicity of clinical rational drug use and safe drug use by the people. In his speech, Lu Hongzhou, deputy editor-in-chief of the, also raised new expectations for the future of the magazine, saying that all editorial board members need to make continuous progress and work together to make The World Clinical Medicine into a well-known academic core journal.Chen Wen, deputy editor-in-chief, said that in the future, we hope to hold more academic seminars with the World Clinical Drugs as a platform. build stronger academic ties with information centers through journal building and create a truly academic highland. Liao Wanqing, a member of the Chinese Academy of Engineering and a second affiliated hospital of the Naval Military Medical University, issued a editorial statement in which he not only affirmed the achievements of the World Clinical Medicines, but also raised the hope for the future development and positioning of the journal. The editorial board held in the morning of was chaired by Lu Weigen, Vice President of the General Institute of Pharmaceutical Industry Research of China, and Zhong Mingkang, Director of the Center for Quality Control of Clinical Medicine Management in Shanghai. Hua Xuewei, deputy director of the China Medical Industry Information Center in , presided over the interactive discussion session of the editorial board, and held a heated discussion with the editorial board on such topics as "the constitution of the editorial board", "the introduction of the contents of the periodical column", the development direction and objectives of periodicals. online editorial board actively participate in the discussion and interaction, in the meeting site Li Bin deputy editor-in-chief, should Xiaohua deputy editor-in-chief, Wang Xiaoling editorial board, Wu Jihong editorial board, Chen Wei editorial board and more than a dozen guests, with the online Zhanglan editorial board, Yang Li editorial board, Lu Zhanzhou editorial board, Ho Yong editorial board, Song Ruiyu editorial board and other academic experts, on the direction of the development of the journal and put forward their views and suggestions. held in the afternoon of the "drug economics and health care" and "clinical application of drugs in the post-epidemic" two sub-forums, the participating editorial boards conducted a wonderful report sharing. at the sub-forum on "Drug Economics and Health Care", Professor Hu Shanlian carried out the interpretation of "conditional payment for innovative drugs". , Professor Sun Lihua of Shenyang Pharmaceutical University, and member of the Editorial Board of the World Clinical Drugs, gave a report entitled "How Drug Economics Should Provide the Basis for Medicare Payment Standards" online. followed, the editorial boards held a round-table discussion on the theme "Drug Economics and Medicare Payment Methods". Round table was chaired by Gan Rongfu, a senior industry researcher and member of the World Clinical Drugs editorial board. Ding Jinxi, Professor of International Medicine Business School, China Pharmaceutical University, Yang Li, Researcher of Peking University School of Public Health, Professor Wu Jihong of the Strategic Support Force Special Medicine Center of the Chinese, Hu Min, Associate Professor of the School of Public Health at Fudan University, and Xuan Jianwei, Professor of the School of Pharmacy at Zhongshan University, as well as The University of Zhongshan University in the United States, discussed the "Discussion on Conditional Payment of Innovative Drugs", "The Discussion of New Adaptation To X-Efus based on Clinical Effects". , "The World Clinical Drugs" deputy editor, the National Health and Health Commission Of the Drug and Technology Comprehensive Assessment Center Deputy Director Professor Zhao Wei in the form of a video report, detailed "how the industry to carry out comprehensive clinical evaluation of drugs." , Professor Wu Jing of the School of Pharmaceutical Science and Technology of Tianjin University, made a report on the theme of "Thinking about the rational use of drug economics in the use of drugs". the second round-table discussion on the theme of "Evaluation and Application of Drug Economics" was chaired by Zhai, Executive Deputy Director of the National Drug Policy and Pharmaceutical Industry Economic Research Center of the Chinese Pharmaceutical University. Professor of Xinhua Hospital affiliated with Shanghai Jiaotong University, Director of Shanghai Foundation for the Prevention and Control of Rare Diseases, Li Hongchao, Director of the Department of Health Economics, International Medical Business School of China Pharmaceutical University, Zhang Weiying, Associate Professor of The School of Public Health of Fudan University, and Xia Sujian, Director of the Medical Statistics Department of jinan University School of Basic Medicine, jointly discussed the "Economic Evaluation of Drugs in the Accelerated Market of Innovative Drugs", "The Feasibility of Dynamic Drug Economics Evaluation", "The Value of Rare Diseases or Targets". "Forum on Drug Economics and Health Care" chaired by Professor Ying Xiaohua and Associate Professor Hu Min of Fudan University School of Public Health. li Bin, deputy editor of "Clinical Drugs in the World Clinical Drugs" and vice president of Yueyang Chinese and Western Medicine Association Hospital, affiliated with Shanghai University of Traditional Chinese Medicine, delivered a speech as chairman of the sub-forum at the sub-forum. Professor Zhou Xin, deputy editor of the World Clinical Medicine sat in and director of respiratory and critical care medicine at Shanghai First People's Hospital, introduced the "drug treatment of anti-epidemic and new crown pneumonia". Lu Hongzhou, deputy editor of the World Clinical Drugs and secretary of the Party Committee of the Public Health Clinical Center in Shanghai (affiliated with Fudan University), gave a keynote speech on "Comprehensive Diagnosis and Treatment of New Crown Pneumonia". Ji Jianlin, a physician at Zhongshan Hospital affiliated with Fudan University and a member of the editorial board of the World Clinical Drugs and a subsidiary of Fudan University, analyzed the "New Crown Epidemic and Mental Health". He Xijing, deputy editor of the World Clinical Medicine s at the and president of Xi'an International Rehabilitation Medical Center, interpreted "new ideas for clinical drug use in the post-epidemic era". the editorial board of the World Clinical Medicines and the director of chinese and Western medicine in Yueyang, affiliated with Shanghai University of Traditional Chinese Medicine, and Min Min, director of cardiology at the Hospital of Chinese and Western Medicine, an affiliate of Shanghai University of Traditional Chinese Medicine, analyzed the report of "The Revelation of War Epidemic: The Role of Chinese and Western Medicine in the Treatment of New Crown Pneumonia". finally, Gu Wei, a member of the editorial board of the World Clinical Drugs and director of Nanjing Hospital affiliated with Nanjing Medical University, made a keynote report entitled "Management of Respiratory Slow Disease in the Post-Epidemic". forum on "Clinical Application of Drugs in Post-Epidemic" was chaired by Dr. Chen Wei, Director of Ruijin North Hospital, Shanghai Jiaotong University School of Medicine, and Wang Ruiping, Director of the Clinical Research Center of Yueyang Chinese and Western Medicine Combined Hospital, affiliated with Shanghai University of Traditional Chinese Medicine. .